logo
logo

Electra Therapeutics Announces $84 Million Series B Financing And Unveils Its Novel Sirp‑Targeted Therapies For Immunological Diseases And Cancer

Feb 16, 2022•over 3 years ago

Amount Raised

$84 Million

Round Type

series b

San Francisco

Description

Electra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies that target signal regulatory proteins (SIRP), announced today a $84 million Series B financing co-led by Westlake Village BioPartners and OrbiMed. Other participating investors include Redmile Group, Cormorant Asset Management, Cowen Healthcare Investments, RA Capital, and New Leaf Venture Partners. Electra was previously funded by its parent company, Star Therapeutics.

Company Information

Company

Electra Therapeutics

Location

San Francisco, California, United States

About

Electra Therapeutics is a clinical stage biotechnology company developing therapies that target signal regulatory proteins (SIRP) for the treatment of immunological diseases and cancer. Electra currently has one program in clinical development and two additional preclinical programs. The company’s lead product candidate, ELA026, is a monoclonal antibody that targets SIRP on the cell surface of myeloid and T cells, and depletes pathological immune cells. ELA026 is in clinical development for secondary hemophagocytic lymphohistiocytosis (sHLH), a life-threatening hyperinflammatory condition for which there is no approved treatment. For more information, please visit Electra Therapeutics and follow us on Twitter @ELECTRA_Biotech and LinkedIn.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech